단백질 치료제 시장 분석 및 예측 : 유형, 제품 유형, 기술, 용도, 최종 사용자, 형태, 프로세스, 설치 유형, 장비(-2035년)

Protein Therapeutics Market is anticipated to expand from $376.0 Billion in 2024 to $740.8 Billion by 2034, growing at a CAGR of approximately 7%. The Protein Therapeutics Market encompasses biologically-derived treatments using proteins to address various medical conditions. This market includes monoclonal antibodies, vaccines, and peptide hormones, offering targeted therapies with high specificity. The increasing prevalence of chronic diseases and advancements in biotechnology fuel market growth, with innovations in protein engineering and delivery systems enhancing therapeutic efficacy and patient outcomes. Regulatory support and rising healthcare expenditures further bolster market expansion.

Global tariffs and geopolitical tensions are profoundly influencing the Protein Therapeutics Market, particularly in East Asia. Japan and South Korea are strategically investing in biopharmaceutical innovation to mitigate reliance on imports and counter tariff impacts. China is accelerating its biopharma capabilities, focusing on self-sufficiency amidst export restrictions, while Taiwan leverages its advanced manufacturing to remain a pivotal player despite geopolitical vulnerabilities. The global protein therapeutics market is robust, driven by advancements in biologics and personalized medicine. By 2035, growth is anticipated to be sustained through regional collaborations and innovation in biosimilars. Middle East conflicts indirectly affect this market by exacerbating energy price volatility, which could disrupt manufacturing and logistics, highlighting the need for resilient supply chain strategies.

The Protein Therapeutics Market is experiencing robust growth, driven by advancements in biotechnology and increasing prevalence of chronic diseases. The monoclonal antibodies segment leads in performance, due to their specificity and effectiveness in treating various conditions. Within this segment, cancer and autoimmune diseases are top-performing sub-segments, reflecting their significant therapeutic potential. The therapeutic proteins segment follows closely, with enzymes and hormones being pivotal in addressing metabolic and hormonal disorders.

Fusion proteins are also gaining traction, particularly in oncology and infectious diseases, offering enhanced efficacy and reduced side effects. The demand for biosimilars is rising, driven by cost-effectiveness and the expiration of patents for several biologics, providing lucrative opportunities for market players. Innovations in drug delivery systems and personalized medicine are further propelling the market. Strategic collaborations and investments in R&D are crucial for capturing emerging opportunities and sustaining competitive advantage in this dynamic landscape.

The Protein Therapeutics Market is characterized by diverse market share, with a dynamic pricing landscape influenced by technological advancements and strategic alliances. Recent product launches have invigorated the market, reflecting innovation and a focus on addressing unmet medical needs. Key players are actively engaged in expanding their portfolios, enhancing therapeutic efficacy, and targeting niche segments. The market is witnessing a shift towards personalized medicine, driving demand for novel protein-based therapies. North America remains a dominant force, while emerging economies present lucrative opportunities for growth.

Competition benchmarking reveals a landscape marked by intense rivalry and strategic collaborations. Companies are leveraging cutting-edge technologies to gain competitive advantages. Regulatory influences play a pivotal role, with stringent guidelines in North America and Europe shaping market dynamics. The regulatory environment fosters innovation while ensuring patient safety. Emerging markets are adapting to global standards, presenting both challenges and opportunities. The market's trajectory is poised for growth, driven by scientific advancements and increasing healthcare investments. Challenges such as high development costs and complex regulatory pathways persist, yet the potential for groundbreaking therapies remains substantial.

Geographical Overview:

The protein therapeutics market is witnessing robust growth across various regions, each presenting unique opportunities. North America remains at the forefront, driven by advanced healthcare infrastructure and significant R&D investments. The presence of key industry players further bolsters the region's market dominance. Europe follows closely, with strong government support and a focus on biopharmaceutical innovation enhancing market prospects. The region's emphasis on personalized medicine and biotechnology fuels growth.

In the Asia-Pacific region, the market is expanding rapidly due to increasing healthcare expenditures and a growing prevalence of chronic diseases. Countries like China and India are emerging as lucrative markets, owing to their large patient populations and rising demand for novel therapies. Latin America and the Middle East & Africa are also gaining traction. In Latin America, improvements in healthcare access and infrastructure drive market potential, while the Middle East & Africa benefit from increased investments in biotechnology and healthcare advancements.

Recent Developments:

The protein therapeutics market has experienced noteworthy developments over the past three months. Amgen announced a strategic collaboration with a leading biotech firm to enhance its protein engineering capabilities, aiming to accelerate drug discovery and development processes. This partnership is expected to significantly bolster Amgen\u2019s position in the protein therapeutics landscape.

In another significant move, Roche acquired a promising biotech company specializing in the development of novel protein-based therapies. This acquisition is set to enhance Roche\u2019s portfolio, providing access to innovative therapeutic candidates poised to address unmet medical needs across various therapeutic areas.

Regulatory advancements have also been prominent, with the FDA granting fast-track designation to a groundbreaking protein therapeutic developed by Biogen, aimed at treating a rare genetic disorder. This regulatory milestone underscores the potential of protein therapeutics in addressing complex medical conditions.

Meanwhile, Pfizer unveiled a cutting-edge protein therapeutic targeting a prevalent chronic disease, marking a significant addition to its existing product lineup. The launch is anticipated to drive substantial market growth, given the therapeutic\u2019s innovative mechanism of action.

Lastly, a joint venture between two pharmaceutical giants was announced, focusing on the development of next-generation protein therapeutics. This collaboration aims to leverage advanced technologies to create more effective and targeted therapies, highlighting the ongoing evolution and dynamism within the protein therapeutics market.

Key Trends and Drivers:

The Protein Therapeutics Market is experiencing robust growth, driven by advancements in biotechnology and a surge in chronic disease prevalence. Biopharmaceutical innovations are leading to the development of novel protein-based therapies, enhancing treatment efficacy and patient outcomes. These therapies are increasingly favored due to their specificity and reduced side effects compared to traditional pharmaceuticals.

A key trend is the expansion of monoclonal antibodies, which are gaining traction for their targeted action against cancer and autoimmune diseases. The market is also witnessing a rise in demand for biosimilars, driven by the expiration of patents and the need for cost-effective alternatives. This trend is further supported by regulatory frameworks that facilitate biosimilar approvals, expediting market entry.

Additionally, personalized medicine is emerging as a significant driver, with protein therapeutics playing a crucial role in tailoring treatments to individual genetic profiles. Investments in research and development are fostering innovation, while collaborations between biotech firms and academic institutions are accelerating discovery processes. The growing emphasis on precision medicine and targeted therapies is creating lucrative opportunities in the protein therapeutics landscape, promising substantial market expansion in the coming years.

Restraints and Challenges:

The protein therapeutics market is confronted with several significant restraints and challenges. One prominent challenge is the high cost of development and production, which increases the financial burden on manufacturers and consumers. Regulatory hurdles further complicate market entry, as stringent compliance requirements demand substantial time and resources. Intellectual property issues also present a barrier, with patent expirations leading to increased competition from biosimilars. Additionally, the complex nature of protein therapeutics necessitates advanced storage and distribution infrastructure, adding logistical difficulties and costs. Finally, limited patient access due to high prices and reimbursement issues restricts market expansion, particularly in developing regions. These factors collectively impede the growth and accessibility of the protein therapeutics market.

Key Companies:

Biocon, Sangamo Therapeutics, AbCellera Biologics, MacroGenics, Adaptimmune Therapeutics, BioNTech, CureVac, ImmunoGen, Kymab, Morphic Therapeutic, Pieris Pharmaceuticals, Sorrento Therapeutics, Argenx, Aptevo Therapeutics, Alector, Zymeworks, Allakos, Gritstone Oncology, Gossamer Bio, Harpoon Therapeutics

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Technology
• 2.4 Key Market Highlights by Application
• 2.5 Key Market Highlights by End User
• 2.6 Key Market Highlights by Form
• 2.7 Key Market Highlights by Process
• 2.8 Key Market Highlights by Installation Type
• 2.9 Key Market Highlights by Equipment

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Monoclonal Antibodies
  • 4.1.2 Insulin
  • 4.1.3 Erythropoietin
  • 4.1.4 Interferons
  • 4.1.5 Colony Stimulating Factors
  • 4.1.6 Growth Hormones
  • 4.1.7 Coagulation Factors
  • 4.1.8 Enzyme Replacement
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Therapeutic Proteins
  • 4.2.2 Vaccines
  • 4.2.3 Peptide Hormones
  • 4.2.4 Blood Factors
• 4.3 Market Size & Forecast by Technology (2020-2035)
  • 4.3.1 Recombinant DNA Technology
  • 4.3.2 Hybridoma Technology
  • 4.3.3 Transgenic Technology
  • 4.3.4 Cell Culture
• 4.4 Market Size & Forecast by Application (2020-2035)
  • 4.4.1 Cancer
  • 4.4.2 Metabolic Disorders
  • 4.4.3 Blood Disorders
  • 4.4.4 Autoimmune Diseases
  • 4.4.5 Infectious Diseases
  • 4.4.6 Neurological Disorders
• 4.5 Market Size & Forecast by End User (2020-2035)
  • 4.5.1 Hospitals
  • 4.5.2 Clinics
  • 4.5.3 Research Institutes
  • 4.5.4 Biopharmaceutical Companies
• 4.6 Market Size & Forecast by Form (2020-2035)
  • 4.6.1 Injectable
  • 4.6.2 Oral
  • 4.6.3 Inhalable
  • 4.6.4 Topical
• 4.7 Market Size & Forecast by Process (2020-2035)
  • 4.7.1 Purification
  • 4.7.2 Formulation
  • 4.7.3 Lyophilization
• 4.8 Market Size & Forecast by Installation Type (2020-2035)
  • 4.8.1 In-House
  • 4.8.2 Outsourced
• 4.9 Market Size & Forecast by Equipment (2020-2035)
  • 4.9.1 Bioreactors
  • 4.9.2 Chromatography Systems
  • 4.9.3 Filtration Systems

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Technology
    • 5.2.1.4 Application
    • 5.2.1.5 End User
    • 5.2.1.6 Form
    • 5.2.1.7 Process
    • 5.2.1.8 Installation Type
    • 5.2.1.9 Equipment
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Technology
    • 5.2.2.4 Application
    • 5.2.2.5 End User
    • 5.2.2.6 Form
    • 5.2.2.7 Process
    • 5.2.2.8 Installation Type
    • 5.2.2.9 Equipment
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Technology
    • 5.2.3.4 Application
    • 5.2.3.5 End User
    • 5.2.3.6 Form
    • 5.2.3.7 Process
    • 5.2.3.8 Installation Type
    • 5.2.3.9 Equipment
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Technology
    • 5.3.1.4 Application
    • 5.3.1.5 End User
    • 5.3.1.6 Form
    • 5.3.1.7 Process
    • 5.3.1.8 Installation Type
    • 5.3.1.9 Equipment
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Technology
    • 5.3.2.4 Application
    • 5.3.2.5 End User
    • 5.3.2.6 Form
    • 5.3.2.7 Process
    • 5.3.2.8 Installation Type
    • 5.3.2.9 Equipment
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Technology
    • 5.3.3.4 Application
    • 5.3.3.5 End User
    • 5.3.3.6 Form
    • 5.3.3.7 Process
    • 5.3.3.8 Installation Type
    • 5.3.3.9 Equipment
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Technology
    • 5.4.1.4 Application
    • 5.4.1.5 End User
    • 5.4.1.6 Form
    • 5.4.1.7 Process
    • 5.4.1.8 Installation Type
    • 5.4.1.9 Equipment
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Technology
    • 5.4.2.4 Application
    • 5.4.2.5 End User
    • 5.4.2.6 Form
    • 5.4.2.7 Process
    • 5.4.2.8 Installation Type
    • 5.4.2.9 Equipment
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Technology
    • 5.4.3.4 Application
    • 5.4.3.5 End User
    • 5.4.3.6 Form
    • 5.4.3.7 Process
    • 5.4.3.8 Installation Type
    • 5.4.3.9 Equipment
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Technology
    • 5.4.4.4 Application
    • 5.4.4.5 End User
    • 5.4.4.6 Form
    • 5.4.4.7 Process
    • 5.4.4.8 Installation Type
    • 5.4.4.9 Equipment
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Technology
    • 5.4.5.4 Application
    • 5.4.5.5 End User
    • 5.4.5.6 Form
    • 5.4.5.7 Process
    • 5.4.5.8 Installation Type
    • 5.4.5.9 Equipment
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Technology
    • 5.4.6.4 Application
    • 5.4.6.5 End User
    • 5.4.6.6 Form
    • 5.4.6.7 Process
    • 5.4.6.8 Installation Type
    • 5.4.6.9 Equipment
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Technology
    • 5.4.7.4 Application
    • 5.4.7.5 End User
    • 5.4.7.6 Form
    • 5.4.7.7 Process
    • 5.4.7.8 Installation Type
    • 5.4.7.9 Equipment
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Technology
    • 5.5.1.4 Application
    • 5.5.1.5 End User
    • 5.5.1.6 Form
    • 5.5.1.7 Process
    • 5.5.1.8 Installation Type
    • 5.5.1.9 Equipment
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Technology
    • 5.5.2.4 Application
    • 5.5.2.5 End User
    • 5.5.2.6 Form
    • 5.5.2.7 Process
    • 5.5.2.8 Installation Type
    • 5.5.2.9 Equipment
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Technology
    • 5.5.3.4 Application
    • 5.5.3.5 End User
    • 5.5.3.6 Form
    • 5.5.3.7 Process
    • 5.5.3.8 Installation Type
    • 5.5.3.9 Equipment
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Technology
    • 5.5.4.4 Application
    • 5.5.4.5 End User
    • 5.5.4.6 Form
    • 5.5.4.7 Process
    • 5.5.4.8 Installation Type
    • 5.5.4.9 Equipment
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Technology
    • 5.5.5.4 Application
    • 5.5.5.5 End User
    • 5.5.5.6 Form
    • 5.5.5.7 Process
    • 5.5.5.8 Installation Type
    • 5.5.5.9 Equipment
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Technology
    • 5.5.6.4 Application
    • 5.5.6.5 End User
    • 5.5.6.6 Form
    • 5.5.6.7 Process
    • 5.5.6.8 Installation Type
    • 5.5.6.9 Equipment
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Technology
    • 5.6.1.4 Application
    • 5.6.1.5 End User
    • 5.6.1.6 Form
    • 5.6.1.7 Process
    • 5.6.1.8 Installation Type
    • 5.6.1.9 Equipment
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Technology
    • 5.6.2.4 Application
    • 5.6.2.5 End User
    • 5.6.2.6 Form
    • 5.6.2.7 Process
    • 5.6.2.8 Installation Type
    • 5.6.2.9 Equipment
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Technology
    • 5.6.3.4 Application
    • 5.6.3.5 End User
    • 5.6.3.6 Form
    • 5.6.3.7 Process
    • 5.6.3.8 Installation Type
    • 5.6.3.9 Equipment
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Technology
    • 5.6.4.4 Application
    • 5.6.4.5 End User
    • 5.6.4.6 Form
    • 5.6.4.7 Process
    • 5.6.4.8 Installation Type
    • 5.6.4.9 Equipment
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Technology
    • 5.6.5.4 Application
    • 5.6.5.5 End User
    • 5.6.5.6 Form
    • 5.6.5.7 Process
    • 5.6.5.8 Installation Type
    • 5.6.5.9 Equipment

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Biocon
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Sangamo Therapeutics
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 AbCellera Biologics
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 MacroGenics
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Adaptimmune Therapeutics
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 BioNTech
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 CureVac
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 ImmunoGen
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Kymab
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Morphic Therapeutic
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Pieris Pharmaceuticals
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Sorrento Therapeutics
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Argenx
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Aptevo Therapeutics
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Alector
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Zymeworks
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Allakos
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Gritstone Oncology
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Gossamer Bio
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Harpoon Therapeutics
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us